Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCM NASDAQ:IMVT NASDAQ:KYMR NYSE:NUVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$17.27-2.9%$15.99$11.51▼$21.50$3.10B0.5539,756 shs45,952 shsIMVTImmunovant$15.71-2.3%$16.41$12.72▼$34.47$2.75B0.661.30 million shs1.53 million shsKYMRKymera Therapeutics$42.96-1.8%$43.85$19.44▼$53.27$2.85B2.18557,010 shs393,426 shsNUVBNuvation Bio$2.22-5.9%$2.19$1.54▼$3.45$803.02M1.354.90 million shs3.60 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED-2.87%-1.93%+10.07%+15.13%-11.16%IMVTImmunovant-2.30%-7.32%-6.54%-0.57%-45.96%KYMRKymera Therapeutics-1.81%-6.18%-3.53%+21.77%-7.01%NUVBNuvation Bio-5.73%-11.02%+8.03%-9.76%-42.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHCMHUTCHMED3.1802 of 5 stars3.34.00.00.03.30.01.9IMVTImmunovant1.4287 of 5 stars3.40.00.00.02.51.70.0KYMRKymera Therapeutics3.5621 of 5 stars4.63.00.00.03.42.50.0NUVBNuvation Bio2.2712 of 5 stars3.60.00.00.02.54.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCMHUTCHMED 2.50Moderate Buy$28.0062.13% UpsideIMVTImmunovant 2.82Moderate Buy$36.40131.70% UpsideKYMRKymera Therapeutics 3.10Buy$59.1137.60% UpsideNUVBNuvation Bio 3.20Buy$7.17222.82% UpsideCurrent Analyst Ratings BreakdownLatest NUVB, HCM, IMVT, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025KYMRKymera TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$60.007/28/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$17.00 ➝ $18.007/22/2025HCMHUTCHMEDBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $28.007/15/2025KYMRKymera TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$18.007/3/2025KYMRKymera TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$70.006/27/2025KYMRKymera TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$56.00 ➝ $53.006/26/2025KYMRKymera TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.006/26/2025KYMRKymera TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$57.00 ➝ $53.006/26/2025KYMRKymera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $60.006/25/2025KYMRKymera TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$64.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCMHUTCHMED$630.20M4.78$0.28 per share61.90$4.43 per share3.90IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AKYMRKymera Therapeutics$47.07M59.43N/AN/A$12.90 per share3.33NUVBNuvation Bio$7.87M95.98N/AN/A$1.37 per share1.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCMHUTCHMED$37.73MN/A0.0011.83N/AN/AN/AN/A8/7/2025 (Estimated)IMVTImmunovant-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)KYMRKymera Therapeutics-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)NUVBNuvation Bio-$567.94M-$2.35N/AN/AN/A-5,534.21%-44.14%-32.97%8/7/2025 (Estimated)Latest NUVB, HCM, IMVT, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NUVBNuvation Bio-$0.17N/AN/AN/A$0.42 millionN/A8/6/2025Q2 2025KYMRKymera Therapeutics-$0.84N/AN/AN/A$17.37 millionN/A8/5/2025Q1 2026IMVTImmunovant-$0.69N/AN/AN/AN/AN/A5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/9/2025Q1 2025KYMRKymera Therapeutics-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million5/7/2025Q1 2025NUVBNuvation Bio-$0.16-$0.16N/A-$0.16$0.42 million$3.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCMHUTCHMEDN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCMHUTCHMED0.082.832.70IMVTImmunovantN/A11.1611.16KYMRKymera TherapeuticsN/A8.498.49NUVBNuvation BioN/A9.019.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCMHUTCHMED8.82%IMVTImmunovant47.08%KYMRKymera TherapeuticsN/ANUVBNuvation Bio61.67%Insider OwnershipCompanyInsider OwnershipHCMHUTCHMED3.60%IMVTImmunovant1.80%KYMRKymera Therapeutics16.01%NUVBNuvation Bio29.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableIMVTImmunovant120171.07 million167.99 millionOptionableKYMRKymera Therapeutics17065.12 million54.69 millionOptionableNUVBNuvation Bio60340.26 million238.42 millionOptionableNUVB, HCM, IMVT, and KYMR HeadlinesRecent News About These CompaniesNuvation Bio (NUVB)’s Taletrectinib Selected as Preferred Agent for Cancer TreatmentAugust 1 at 11:35 AM | finance.yahoo.comGSA Capital Partners LLP Has $1.16 Million Stock Position in Nuvation Bio Inc. (NYSE:NUVB)August 1 at 5:40 AM | marketbeat.comRBC Capital Maintains a Buy on Nuvation Bio (NUVB) With a $6 PTAugust 1 at 2:32 AM | msn.comInstitutional investors may adopt severe steps after Nuvation Bio Inc.'s (NYSE:NUVB) latest 5.9% drop adds to a year lossesJuly 31 at 8:32 PM | finance.yahoo.comNuvation Bio (NUVB) Expected to Announce Earnings on ThursdayJuly 31 at 2:59 AM | marketbeat.comNuvation Bio (NYSE:NUVB) Trading 8.6% Higher - Should You Buy?July 29, 2025 | marketbeat.comWall Street Zen Upgrades Nuvation Bio (NYSE:NUVB) to HoldJuly 28, 2025 | americanbankingnews.comNuvation Bio (NYSE:NUVB) Upgraded at Wall Street ZenJuly 26, 2025 | marketbeat.comNuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025July 24, 2025 | businesswire.comNuvation Bio (NYSE:NUVB) Trading Up 5.4% - What's Next?July 16, 2025 | marketbeat.comNuvation Bio (NYSE:NUVB) Stock Price Down 5.2% - Should You Sell?July 14, 2025 | marketbeat.comAll You Need to Know About Nuvation Bio (NUVB) Rating Upgrade ... - NasdaqJuly 11, 2025 | nasdaq.comAll You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to BuyJuly 9, 2025 | zacks.comNuvation Bio (NYSE:NUVB) Shares Gap Up - What's Next?July 9, 2025 | marketbeat.comNuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 7, 2025 | marketbeat.comNuvation Bio Inc. (NUVB) latest stock news and headlines - Yahoo FinanceJuly 2, 2025 | uk.finance.yahoo.comJMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch PlansJune 29, 2025 | msn.comRBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy RatingJune 24, 2025 | msn.comNuvation Bio jumps after insiders purchase shares worth over $1.1MJune 20, 2025 | msn.comFounder of Nuvation Bio David Hung Buys More StockJune 20, 2025 | finance.yahoo.comNuvation Bio price target lowered to $6 from $10 at RBC CapitalJune 18, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNUVB, HCM, IMVT, and KYMR Company DescriptionsHUTCHMED NASDAQ:HCM$17.27 -0.51 (-2.87%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$17.23 -0.04 (-0.26%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Immunovant NASDAQ:IMVT$15.71 -0.37 (-2.30%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$15.55 -0.16 (-1.02%) As of 08/1/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Kymera Therapeutics NASDAQ:KYMR$42.96 -0.79 (-1.81%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$42.92 -0.04 (-0.09%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Nuvation Bio NYSE:NUVB$2.22 -0.14 (-5.93%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$2.21 -0.01 (-0.45%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
